Swedish pharmaceutical company Cinclus Pharma Holding AB (“Cinclus Pharma”), recently announced the appointment of Jenni Björnulfson as its Chief Financial Officer.
According to the company, Jenni will initially start the position on a part time basis, before transitioning to full time later in 2020.
Jenni has extensive professional experience from the financial markets and the healthcare sector. Having worked among other things in corporate finance for over ten years with Handelsbanken Markets and Alfred Berg Fondkommission/ABM AMRO, she has also been Service Line Lead Manager at GHP Specialty Care AB.
A graduate from Stockholm School of Economics, Jenni was most recently the CFO of Promore Pharma AB since 2016.
“We are delighted to welcome Jenni to Cinclus Pharma’s expanding Management team,” said Kjell Andersson, CEO Cinclus Pharma.
He further added, “We value that she is bringing her expertise and experience to the company at an exciting time following our recent successful financing round.”
Earlier in March, the company announced that it had successfully completed financing which provided SEK 250 million to fund the further clinical development of X842 – a clinical-stage drug candidate for the treatment of gastroesophageal reflux disease (GERD) that is being prepared for a clinical phase II study. X842 has the potential to alleviate GERD symptoms and heal esophageal injuries more effectively than current pharmaceutical therapies.
Cinclus Pharma’s drug candidate X842 represents a novel class of pharmaceuticals (Potassium Competitive Acid Blockers, P-CAB), which utilizes a different mode of action to modulate and control the release of gastric acid, as compared to PPIs.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.